Retraction: Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor (Molecular Cancer Therapeutics (2008)7 (800–808) DOI: 10.1158/1535-7163.MCT-07-0434)

Shu Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro, Ching Shih Chen

Research output: Contribution to journalComment/debate

Abstract

This article (1) has been retracted at the request of the editors. Following institutional review by the Ohio State University it was determined that Fig. 4A and B were intentionally falsified by Dr. Ching-Shih Chen. The authors regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article. A copy of this Retraction Notice was sent to the last known email addresses for the authors. Three authors (S.K. Kulp, R.W. Brueggemeier, and C.L. Shapiro) agreed to the retraction; the four remaining authors (S-C. Weng, Y. Kashida, D. Wang, and C-S. Chen) could not be located.

Original languageEnglish
Pages (from-to)869
Number of pages1
JournalMolecular Cancer Therapeutics
Volume18
Issue number4
DOIs
StatePublished - Apr 2019

Fingerprint

Dive into the research topics of 'Retraction: Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor (Molecular Cancer Therapeutics (2008)7 (800–808) DOI: 10.1158/1535-7163.MCT-07-0434)'. Together they form a unique fingerprint.

Cite this